MedTrace Logo

A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer

NCT00055471 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2012-10-31

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to determine the safest dose of ZD4054 (Zibotentan)in men with prostate cancer

Conditions

  • Prostatic Neoplasms
  • Metastases, Neoplasm

Interventions

DRUG

ZD4054 10 mg

1 x 10 mg oral tablets once daily

DRUG

ZD4054 15 mg

1 x 10 mg + 2 x 2.5 mg oral tablets once daily

DRUG

ZD4054 22.5 mg

2 x 10 mg + 2 x 2.5 mg oral tablets once daily

Sponsors & Collaborators

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Primary Completion
2005-10-31
Completion
2005-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00055471 on ClinicalTrials.gov